Hepatitis B vaccine

VBI Vaccines Reports Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 16, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shekel, Sale, Net, GAAP, MLE, Walmart, Pharmacy, Green Book, Government, Hepatitis B vaccine, Green, Prison, Research and development, Partnership, Control arm, GBM, Vaccine, Administration, Disease, Exercise, Patient, Carmustine, CAD, VBI, Hepatitis B, Messenger, Bank statement, Israeli new shekel, Internationalized domain name, Growth, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
  • Revenues, net: Revenues, net for the full year 2023 were $8.7 million as compared to $1.1 million for the same period in 2022.
  • Cost of Revenues: Cost of revenues was $12.5 million for the full year 2023 as compared to $11.3 million in 2022.
  • Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

VBI Vaccines Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, Shekel, MLE, High-net-worth individual, Hepatitis B vaccine, GMT, HBsAg, Net, AASLD, Bank statement, Disease, GBM, Government, Administration, Patient, HBV, Research and development, Prison, Allergy, Fast track (FDA), Autoimmune disease, InSight, Liver, VBI, Messenger, Internationalized domain name, GAAP, Vaccine, Cancer, Partnership, R, Seroconversion, Growth, Infection, Israeli new shekel, Pharmaceutical industry, Video game, Rare-earth element, Cryptocurrency, Bank

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023.
  • Cost of Revenues: Cost of revenues was $2.5 million in the third quarter of 2023 as compared to $2.7 million in the third quarter of 2022.
  • Research and Development (R&D): R&D expenses for the third quarter of 2023 were $1.5 million as compared to $5.0 million for the third quarter of 2022.
  • Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

VBI Vaccines Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shekel, Vaccine, Impairment, Prison, Medicaid, Partnership, SG, GBM, CPT, Marketing, NRC, SARS-CoV-2, Bank statement, COVID-19, Net, SARS, Hepatitis B, Hepatitis B vaccine, GAAP, MERS-related coronavirus, VBI, Israeli new shekel, Government, Fast track (FDA), CDC, High-net-worth individual, Medicare, Research and development, MERS, ...Continued, Anthrax Vaccine Immunization Program, ISED, Patient, Administration, Recombinant, InSight, Growth, Internationalized domain name, R, Syneos Health, HBV, National Research Council, Disease, Pharmaceutical industry, Video game, Bank, Adsorption

Cost of Revenues: Cost of revenues was $3.5 million in the second quarter of 2023 as compared to $2.5 million in the second quarter of 2022.

Key Points: 
  • Cost of Revenues: Cost of revenues was $3.5 million in the second quarter of 2023 as compared to $2.5 million in the second quarter of 2022.
  • Research and Development (R&D): R&D expenses for the second quarter of 2023 were $3.3 million as compared to $5.6 million for the second quarter of 2022.
  • Impairment for the second quarter of 2023 was $20.0 million as compared to $0 for the second quarter of 2022.
  • Foreign exchange loss for the second quarter of 2023 was $5.9 million as compared to $21.9 million for the second quarter of 2022.

 VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares

Retrieved on: 
Monday, July 24, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Exercise, Attention, Telephone, Enterprise file synchronization and sharing, Hepatitis B vaccine, VBI, Glioblastoma, Sale, Public expenditure, Prospectus, Form, Security (finance), Syndicate, Disease

VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the underwriters of its recent underwritten public offering of common shares and accompanying common warrants to purchase common shares partially exercised their option to purchase an additional 1,536,363 common shares at a public offering price of $1.64 per common share.

Key Points: 
  • VBI Vaccines Inc. (NASDAQ: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the underwriters of its recent underwritten public offering of common shares and accompanying common warrants to purchase common shares partially exercised their option to purchase an additional 1,536,363 common shares at a public offering price of $1.64 per common share.
  • The partial option exercise closed on July 21, 2023.
  • Immediately following the closing of the partial option exercise, the number of outstanding common shares of the Company is 22,872,175.
  • Raymond James & Associates, Inc. acted as the sole book-running manager for the underwritten public offering.

VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Retrieved on: 
Wednesday, July 19, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Other Health, Health, Science, Oncology, Infection, Hepatitis B vaccine, Partnership, Marketing, Hepatitis B, Hepatitis B virus, VBI, Hepatitis D, Immunization, Vaccine, HBV, Disease, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the Netherlands and Belgium for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the Netherlands and Belgium for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.
  • It can be expected that hepatitis D will also be prevented by immunization with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
  • As part of the marketing and distribution partnership announced in September 2022, PreHevbri will be available in the Netherlands and Belgium through Valneva’s existing commercial infrastructure and distribution networks.
  • Jeff Baxter, President and CEO of VBI, commented: “We are excited to announce the launch of PreHevbri in the Netherlands and Belgium through our partnership with Valneva.

VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering

Retrieved on: 
Thursday, July 6, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Exercise, Attention, Telephone, Enterprise file synchronization and sharing, Hepatitis B vaccine, VBI, Glioblastoma, Sale, Public expenditure, Prospectus, Form, Security (finance), Syndicate, Disease

VBI also granted the underwriters a 30-day option to purchase up to an additional 1,636,363 common shares and/or common warrants to purchase up to 1,636,363 common shares offered in the underwritten public offering.

Key Points: 
  • VBI also granted the underwriters a 30-day option to purchase up to an additional 1,636,363 common shares and/or common warrants to purchase up to 1,636,363 common shares offered in the underwritten public offering.
  • Raymond James & Associates, Inc. is acting as the sole book-running manager for the underwritten public offering.
  • Newbridge Securities Corporation is acting as the lead manager for the underwritten public offering.
  • The registered direct offering is being made without an underwriter or a placement agent.

VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants

Retrieved on: 
Wednesday, July 5, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Attention, Telephone, Enterprise file synchronization and sharing, Hepatitis B vaccine, VBI, Glioblastoma, Sale, Public expenditure, Prospectus, Form, Security (finance), Syndicate, Disease

VBI Vaccines Inc. ( NASDAQ: VBIV ) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has commenced an underwritten public offering and a registered direct offering of its common shares and accompanying common warrants to purchase its common shares.

Key Points: 
  • VBI Vaccines Inc. ( NASDAQ: VBIV ) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has commenced an underwritten public offering and a registered direct offering of its common shares and accompanying common warrants to purchase its common shares.
  • VBI also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares and/or common warrants offered in the public offering.
  • Raymond James & Associates, Inc. is acting as the sole book-running manager for the underwritten public offering.
  • The registered direct offering is being made without an underwriter or a placement agent.

VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties

Retrieved on: 
Wednesday, July 5, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Hepatitis B vaccine, Hepatitis, Partnership, Public, Hepatitis B, Hepatitis B virus, VBI, Patient, Vaccine, HBV, Disease

VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the expansion of its hepatitis B (HBV) partnership with Brii Biosciences (“Brii Bio”) (Stock code: 2137.HK).

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the expansion of its hepatitis B (HBV) partnership with Brii Biosciences (“Brii Bio”) (Stock code: 2137.HK).
  • Through two license and collaboration agreements, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, to global rights and acquired an exclusive license for PreHevbri, VBI’s 3-antigen hepatitis B vaccine, in the Asia Pacific region (APAC).
  • Jeff Baxter, President and CEO of VBI, stated: “This expanded partnership with Brii Bio is a strong endorsement for our HBV programs and our contribution to the fight against hepatitis B.
  • With over 150 million HBV infected people in APAC, improvements in prevention and treatment strategies in this region are essential.

VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Retrieved on: 
Thursday, June 15, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Infection, Hepatitis B vaccine, Partnership, Marketing, Hepatitis B virus, VBI, Hepatitis D, United Kingdom, Immunization, Vaccine, HBV, Disease, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the United Kingdom (“U.K.”) for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the United Kingdom (“U.K.”) for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.
  • It can be expected that hepatitis D will also be prevented by immunization with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
  • As part of the marketing and distribution partnership announced in September 2022, PreHevbri will be available in the U.K. through Valneva’s existing commercial infrastructure and distribution networks.
  • Jeff Baxter, President and CEO of VBI, commented: “We are delighted to announce the availability of PreHevbri in the U.K., marking the first European market launch of our 3-antigen hepatitis B vaccine, which builds upon the increasing momentum for use in the U.S. (available under the brand name PreHevbrio®).

VBI Vaccines Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shekel, Insurance, Medicaid, Vaccination, Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, GBM, CPT, SG, SARS-CoV-2, Bank statement, COVID-19, Net, SARS, Hope, Hepatitis B, GAAP, Hepatitis B vaccine, MERS-related coronavirus, Costco, VBI, Israeli new shekel, Government, Individual savings account, Medicare, Research and development, Hepatitis, MERS, Walmart, Patient, Administration, Access, Recombinant, Antibody, InSight, Federal Bureau of Prisons, Growth, U.S. Department of Veterans Affairs, Office of Inspector General, Rite Aid, Internationalized domain name, Vaccine, R, HBV, Disease, Corporate development, Pharmaceutical industry, Health insurance, Rare-earth element, Management, Video game, Financial services, Adsorption, Prison

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended March 31, 2023.
  • Cash Position: VBI ended the first quarter of 2023 with $40.4 million in cash as compared with $62.6 million in cash as of December 31, 2022.
  • Cost of Revenues: Cost of revenues was $3.6 million in the first quarter of 2023 as compared to $2.8 million in the first quarter of 2022.
  • Foreign exchange loss for the first quarter 2023 was $6.8 million as compared to a loss of $4.4 million for the first quarter of 2022.